PMID- 19692320
OWN - NLM
STAT- MEDLINE
DCOM- 20100330
LR  - 20211203
IS  - 1938-0682 (Electronic)
IS  - 1558-7673 (Linking)
VI  - 7
IP  - 2
DP  - 2009 Aug
TI  - Eosinophilic rash secondary to temsirolimus.
PG  - E34-6
LID - 10.3816/CGC.2009.n.019 [doi]
AB  - We present a case of a 73-year-old female with metastatic renal cell carcinoma, 
      clear cell histologic subtype, who developed pruritic rash after 2 weeks of 25 mg 
      weekly infusions of temsirolimus. Rash was located on bilateral antecubital areas 
      and posterior knees. Skin biopsy showed spongiotic dermatitis with eosinophils. 
      Based on history and clinical examination, a diagnosis of drug rash secondary to 
      temsirolimus was made. Temsirolimus is a small-molecule inhibitor of the 
      mammalian target of rapamycin (mTOR). Inhibition of mTOR kinase results in cell 
      cycle arrest, antiangiogenesis, and apoptosis. The mechanism of skin toxicity is 
      unknown; however, it can be hypothesized that there is a direct inhibitory effect 
      on signaling pathways that regulate cell growth and tissue repair. The mTOR 
      kinase inhibitor temsirolimus has shown great promise in increasing overall 
      survival in patients with metastatic renal cell carcinoma. Dermatologic 
      toxicities are among the most prevalent and necessitate early recognition and 
      management, in order to maintain quality of life and consistent therapy. The 
      patient presented was initiated on topical clobetasol resulting in rash 
      resolution at a 2-week follow-up visit.
FAU - Gandhi, Mona
AU  - Gandhi M
AD  - Department of Dermatology, Northwestern University's Feinberg School ofMedicine, 
      Chicago, IL, USA.
FAU - Kuzel, Timothy
AU  - Kuzel T
FAU - Lacouture, Mario
AU  - Lacouture M
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Clin Genitourin Cancer
JT  - Clinical genitourinary cancer
JID - 101260955
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Intracellular Signaling Peptides and Proteins)
RN  - 624KN6GM2T (temsirolimus)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - Aged
MH  - Antineoplastic Agents/*adverse effects
MH  - Carcinoma, Renal Cell/drug therapy
MH  - Eosinophils/*drug effects
MH  - Exanthema/*chemically induced
MH  - Female
MH  - Humans
MH  - Intracellular Signaling Peptides and Proteins/*antagonists & inhibitors
MH  - Kidney Neoplasms/drug therapy
MH  - Protein Serine-Threonine Kinases/*antagonists & inhibitors
MH  - Sirolimus/adverse effects/*analogs & derivatives
MH  - TOR Serine-Threonine Kinases
EDAT- 2009/08/21 09:00
MHDA- 2010/03/31 06:00
CRDT- 2009/08/21 09:00
PHST- 2009/08/21 09:00 [entrez]
PHST- 2009/08/21 09:00 [pubmed]
PHST- 2010/03/31 06:00 [medline]
AID - S1558-7673(11)70026-X [pii]
AID - 10.3816/CGC.2009.n.019 [doi]
PST - ppublish
SO  - Clin Genitourin Cancer. 2009 Aug;7(2):E34-6. doi: 10.3816/CGC.2009.n.019.